Abstract
Anticoagulants and thrombolytics are used during several procedures that the interventionalist performs. The use of anticoagulants and thrombolytics in percutaneous interventions of dialysis accesses is safe. The most common complication of the use of anticoagulants and thrombolytics is bleeding. Bleeding from access cannulation sites can be controlled with percutaneous sutures. Bleeding from sites of angioplasty can be treated with prolonged angioplasty and/or stenting. After selective catheterization of an artery, removal of the catheter over a guidewire should be considered. If a tunneled dialysis catheter is needed after the patient has received anticoagulants and/or thrombolytics, central venous patency should be evaluated with an angiogram. If central venous stenoses are noted, then these should be treated before placement of a catheter.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI, American College of Chest Physicians SO Chest. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):141S.
Hirsh J, Anand SS, Halperin JL, Fuster V, American Heart Association. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;103(24):2994.
Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86(2):385.
Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994;93(1):81–8.
Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101(5):502.
Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T. Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis. 1996;28(1):82–5.
de Sancho M, Lema MG, Amiral J, Rand J. Frequency of antibodies directed against heparin-platelet factor 4 in patients exposed to heparin through chronic hemodialysis. Thromb Haemost. 1996;|75(4):695–6.
O’shea SI, Lawson JH, Reddan D, Murphy M, Ortel TL. Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg. 2003;38(3):541–8.
United States renal data system: cardiovascular special studies. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda. 2005.
Lee O, Raque JD, Lee LJ, Wivell W, Block CA, Bettmann MA. Retrospective assessment of risk factors to predict tunneled hemodialysis catheter outcome. J Vasc Interv Radiol. 2004;15(5):|457–61.
Crowther MA, Clase CM, Margetts PJ, Julian J, Lambert K, Sneath D, Nagai R, Wilson S, Ingram AJ. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol. 2002;13(9):2331.
Brunet P, Aillaud MF, San Marco M, Philip-Joet C, Dussol B, Bernard D, Juhan-Vague I, Berland Y. Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. Kidney Int. 1995;48(3):794.
Prakash R, Miller 3rd CC, Suki WN. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis. 1995;26(2):347.
Molino D, De Lucia D, Marotta R, Perna A, Lombardi C, Cirillo M, De Santo NG. In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with Thrombosis. Kidney Int. 2005;68(3):1223.
Abigail Falk MD, Harold Mitty MD, Jeffrey Guller MD, Victoria Teodorescu MD, Jaime Uribarri MD, Joseph Vassalotti MD. Thrombolysis of clotted hemodialysis grafts with tissue-type plasminogen activator. J Vasc Interv Radiol. 2001;12(3):305–11.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Moorthi, K.M.L.S.T. (2014). Anticoagulants and Thrombolytics. In: Yevzlin, A., Asif, A., Salman, L. (eds) Interventional Nephrology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8803-3_5
Download citation
DOI: https://doi.org/10.1007/978-1-4614-8803-3_5
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-8802-6
Online ISBN: 978-1-4614-8803-3
eBook Packages: MedicineMedicine (R0)